Business
ViaDerma, Inc. is Granted Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products
ViaDerma, Inc. is Granted Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nViaDerma, Inc. is Granted Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products\n\nViaDerma, Inc. is Granted Approval to sell VitaStem(TM) its FDA Registered Topical Antibiotic on Amazon.com and Expands Testing into Major US Hospital Chains to Ramp Up Domestic Sales & Begins Production of New Products\n\n\nViaDerma's Manufacturer Delivered the first run of its topical antibiotic being sold as VitaStem by its Sales, Marketing and Distribution Partner Biogenx, Inc.; The Company will now start Producing New Products for Distribution in 400 Retail Stores in Canada for its CBD or Cannabinoids Product Line \n\n LOS ANGELES, CA--(Marketwired - November 21, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has begun sales and distribution of its highly anticipated topical antibiotic ointment. Its marketing, sales and distribution partner, Biogenx, Inc. has been preselling the product, under the name of VitaStem™. Which now retails for $79 and can be purchased online at www.Biogenx.net. The Company plans to start manufacturing the second production run of the product and now has streamlined the manufacturing. The Company expects to ramp up production, monthly as the interested in the product continues to grow. The Company will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for \"Aqueous Topical Applications\" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) \"Intellectual Property Portfolio\" in 2018. The Company's President, Dr. Christopher Otiko said, \"Now that we have streamlined the manufacturing process we are ramping up sales and distribution and...